Jonathan is a life sciences executive with more than 25 years of experience in biotechnology management and is the chief executive officer of Veralox. Previously he served as the chief executive officer of PhaseBio Pharmaceuticals (NASDAQ) where he led the company from early stages through Phase 3 development, including the company’s IPO in 2018. Prior to PhaseBio, Jonathan served as vice president, business development for Amylin Pharmaceuticals until its sale to Bristol-Myers Squibb in 2012; co-founder and vice president, commercial and business development of Corus Pharma, Inc. until its acquisition by Gilead Sciences in 2006; and head of business development for PathoGenesis Corporation, until it’s acquisition by Chiron Corporation in 2000. Jonathan has also held positions in marketing, marketing research and sales at Bristol-Myers Squibb, Wyeth/Lederle International and Syntex Laboratories. Jonathan holds a BS in Mechanical Engineering from UC Berkeley and an MBA from Carnegie Mellon University Tepper School of Business.

• 

  Chief Executive Officer (CEO) in Veralox Therapeutics

  Developing new therapies for life-threatening immuno-inflammatory diseases